Nutrition for the Critically Ill Patient with Hepatic Failure

Nutrition Support for the Critically Ill Patient: A Guide to Practice

Volumn , Issue , 2016, Pages 505-518

  Waller, Adam D ^a   Chaudhary, Ayaz J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85179229072     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420039191-40     Document Type: Chapter

References (61)

1. Trey, C. and Davidson, C., The management of fulminant hepatic failure, Prog. Liver Dis., 3, 292, 1970.
2. Schiadt, F.V. et al., Etiology and prognosis for 295 patients with acute liver failure in the United States, Gastroenterology, 122, A1376, 1997.
3. Lee, W.M. et al., Acute liver failure, N. Engl. J. Med., 329, 1862, 1993.
4. O’Grady, J.G. and Williams, R., Classification of acute liver failure, Lancet, 342, 743, 1993.
5. Riordan, S.M. and Williams, R., Fulminant hepatic failure, Clin. Liver Dis., 4, 25, 2000.
6. Ferenci, P. et al., Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification:final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998, Hepatology, 35, 716, 2002.
7. Blei, A.T. and Larsen, F.S., Pathophysiology of cerebral edema in fulminant hepatic failure, J. Hepatol., 31, 771, 1999.
8. Krasko, A., Deshpande, K., and Bonvino, S., Liver failure, transplantation, and critical care, Crit. Care Clinics, 19, 32, 2003.
9. Rolando, N. et al., Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients, Hepatology, 11, 49, 1990.
10. Rolando, N. et al., Fungal infection: a common unrecognized complication of acute liver failure, J. Hepatol., 12, 1, 1991.
11. Bihari, D. et al., Tissue hypoxia during fulminant hepatic failure, Crit. Care Med., 13, 1034, 1985.
12. Ring-Larsen, H. and Palazzo, U., Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis, Gut, 22, 565, 1981.
13. Martin, L.F. et al., Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia, Crit. Care Med., 21, 19, 1993.
14. Canalese, J. et al., Controlled trial of dexamethasone and mannitol for the cerebral edema of fulminant hepatic failure, Gut, 23, 625, 1982.
15. Tsukamoto, H., Gaal, K., and French, S.W., Insights into the pathogenesis of alcoholic liver necrosis and fibrosis: status report, Hepatology, 12, 599, 1990.
16. Butterworth, R.F., The neurobiology of hepatic encephalopathy, Semin. Liver Dis., 16, 235, 1996.
17. Cordoba, J. and Blei, A.T., Treatment of hepatic encephalopathy, Am. J. Gastroenterol., 92, 1429, 1997.
18. Butterworth, R.F., Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems, Curr. Opin. Neurol., 13, 721, 2000.
19. Basile, A.S. and Jones, E.A., Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy, Hepatology, 25, 1303, 1997.
20. Basile, A.S. et al., Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy, Hepatology, 19, 112, 1994.
21. Barbaro, G. et al., Flumazenil for hepatic encephalopathy grade 3 and 4a in patients with cirrhosis:an Italian multicenter double-blind, placebo-controlled, cross-over study, Hepatology, 28, 374, 1998.
22. James, J.H. et al., Hyperammonemia, plasma amino acid imbalance, and blood-brain amino acid transport: a unified theory of portal-systemic encephalopathy, Lancet, 772, 1979.
23. Morgan, M.Y., Milson, J.P., and Sherlock, S., Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease, Gut, 19, 1068, 1978.
24. Fessel, J.M. and Conn, H.O., An analysis of the causes and prevention of hepatic coma, Gastroenterology, 62, 191, 1972.
25. Vogels, B.A. et al., The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy, J. Hepatol., 26, 387, 1997.
26. Weissenborn, K. et al., Neuropsychological characterization of hepatic encephalopathy, J. Hepatol., 34, 768, 2001.
27. Quero, J.C. et al., The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis, Hepatology, 24, 556, 1996.
28. Laudenberger, J. et al., Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis, Gastroenterology, 112, 1610, 1997.
29. Florent, C. et al., Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vitro study), J. Clin. Invest., 75, 608, 1985.
30. Mortensen, P.B., The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion, Hepatology, 16, 1350, 1992.
31. Atterbury, C.E., Maddrey, W.C., and Conn, H.O., Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial, Am. J. Dig. Dis., 23, 398, 1978.
32. Conn. H.O. et al., Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial, Gastroenterology, 72, 573, 1977.
33. Orlandi, F. et al., Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy:a randomized clinical study, Dig. Dis. Sci., 26, 498, 1981.
34. Strauss, E. et al., Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy, Hepatogastroenterology, 39, 542, 1992.
35. Morgan, M.H., Read, A.E., and Speller, D.C., Treatment of hepatic encephalopathy with metronidazole, Gut, 23, 1, 1982.
36. Pomier-Layrargues, G. et al., Flumazenil in cirrhotic patients in hepatic coma: a randomized doubleblind placebo-controlled crossover trial, Hepatology, 19, 32, 1994.
37. Gyr, K. et al., Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomized, placebo controlled multicenter study, Gut, 39, 319, 1996.
38. Cadranel, J.F. et al., Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a doubleblind pragmatic randomized, placebo study, Eur. J. Gastroenterol. Hepatol., 7, 325, 1995.
39. Als-Nielsen, B., Kjaergard, L.L., and Gluud, C., Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy (Cochrane Review), Cochrane Database Syst. Rev., 4, CD002798, 2001.
40. Goulenok, C. et al., Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis, Aliment. Pharmacol. Ther., 16, 361, 2002.
41. Plauth, M. et al., Post-feeding hyperammonemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration, Gut, 46, 849, 2000.
42. Bustamante, J. et al., Prognostic significance of hepatic encephalopathy in patients with cirrhosis, J. Hepatol., 30, 890, 1999.
43. Lockwood, A.H., Hepatic encephalopathy, Neurologic Clinics, 20, 1, 2002.
44. Powell, E.E. et al., Improvement in chronic hepatocerebral degeneration following liver transplantation, Gastroenterology, 98, 1079, 1990.
45. Nompleggi, D.J. and Bonkovsky, H.L., Nutritional supplementation in chronic liver disease: an analytical review, Hepatology, 19, 519, 1994.
46. DiCecco, S.R. et al., Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation, Mayo Clinic Proc., 64, 95, 1989.
47. Hirsch, S. et al., Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis, J. Parenter. Enter. Nutr., 17, 119, 1993.
48. Solomon, S.M. and Kirby, D.F., The refeeding syndrome: a review, JPEN, 14, 90, 1990.
49. Havala, T. and Shronts, E., Managing the complications associated with refeeding, Nutr. Clin. Pract., 5, 23, 1990.
50. Pomposelli, J.J. and Burns, D.L., Nutrition support in the patient with hepatic failure, in Shikora, S.A., Martindale, R.G., and Schwaitzberg, S.D., eds., Nutritional Considerations in the Intensive Care Unit, 199, Kenall/Hunt Publishing Company, Dubuque, IA, 2002.
51. Cabre, E. et al., Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics, Gastroenterology, 98, 715, 1990.
52. Kondrup, J. and Mueller, M.J., Energy and protein requirements of patients with chronic liver disease, J. Hepatol., 27, 239, 1997.
53. Kearns, P.J. et al., Accelerated improvement of alcoholic liver disease with enteral nutrition, Gastroenterology, 102, 200, 1992.
54. Cerra, F.B. et al., Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial, J. Parenter. Enter. Nutr., 9, 288, 1985.
55. Rossi-Fanelli, F. et al., Effect of glucose and/or branched chain amino acid imbalance in chronic liver failure, J. Parenter. Enter. Nutr., 5, 414, 1981.
56. Wahren, J. et al., Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study, Hepatology, 3, 475, 1983.
57. Naylor, C.D., O’Rourke, K., and Baker, J.P., Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: a meta-analysis, Gastroenterology, 97, 1033, 1989.
58. Marchesini, G. et al., Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial, Gastroenterology, 127, 1792, 2003.
59. Charlton, M., Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives, Gastroenterology, 124, 2003.
60. Bianchi, G.P. et al., Vegetable protein diet and hepatic encephalopathy, J. Intern. Med., 233, 385, 1993.
61. Cabre, E. and Gasull, M.A., Nutritional support in liver disease, Eur. J. Gastroenterol. Hepatol., 7, 528, 1995.